Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc.

Jan 30, 2008 - Iroko Pharmaceuticals announces the acquisition of all non-US commercial rights to Aggrastat(R) (tirofiban HCl) from Merck & Co., Inc.

Outside of the US market, Aggrastat(R) in combination with heparin is indicated for patients with unstable angina or non-Q wave myocardial infarction to prevent cardiac ischemic events, and is also indicated for patients with coronary ischemic syndromes undergoing coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery. Aggrastat(R) is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA).